University of Glasgow
Further Information : http://www.gla.ac.ukhttp://www.gla.ac.uk
University of Glasgow is a research-led university that is recognised internationally for its groundbreaking work. It has more than 6000 staff members and more than 23,000 students. The Institute of Cardiovascular & Medical Sciences (ICAMS), part of the College of Medical, Veterinary and Life Sciences (MVLS), has clinical academics and researchers based across Glasgow using state-of-the art facilities. The focus of the institutes' research is cardiovascular disease using a multidisciplinary approach to modern research through cross thematic interactions. The Systems Biology theme is part of the Systems Medicine and Biomarker research group and our work contains and integrates genomics, transcriptomics and proteomics and translates findings from pre-clinical models to human disease and vice versa.
Holger Husi, Dr. sc. nat. is principal investigator of Systems Biology and Systems Medicine within ICAMS and has received his degree from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. He has more than 20 years experience in biological research, large-scale data generation and analysis and played a leading role in the discovery and analysis of large-scale glutamatergic receptor complexes, Systems analysis of acute kidney injury models, as well as biomarker discovery. He will be the main supervisor of ESR6.
Christian Delles, Dr. med. graduated from the University of Freiburg, Germany, and trained in internal medicine and nephrology at the Department of Nephrology, University of Erlangen-Nürnberg, Germany. He is currently a Reader and Honorary Consultant Physician at the Institute of Cardiovascular and Medical Sciences at the University of Glasgow. His research interest is in vascular biology with oxidative stress and endothelial dysfunction as pathogenetic factors of hypertension and other cardiovascular disorders. He focuses on studies into biomarkers of cardiovascular disease with a particular interest in systems medicine approaches. He will be the second supervisor of ESR6.